Top Institutions in Ophthalmology
Institutions leading in ophthalmology research and clinical trials on novel pharmacologic treatments for anterior segment diseases, including dry eye and presbyopia, are ranked based on their history of pioneering clinical trials, FDA approvals, and translational research in ocular surface disease and presbyopia therapies.
-
#1
Massachusetts Eye and Ear Infirmary
Boston, MA
Massachusetts Eye and Ear is a world leader in clinical research on dry eye disease and presbyopia, with extensive involvement in FDA pivotal trials and translational research on novel ocular therapeutics.
Key Differentiators
- Ophthalmology
- Cornea and External Disease
- Clinical Trials
-
#2
Bascom Palmer Eye Institute, University of Miami
Miami, FL
Bascom Palmer is recognized for its pioneering clinical trials in dry eye disease and presbyopia, with a strong focus on innovative drug development and patient-centered outcomes.
Key Differentiators
- Ophthalmology
- Cornea and External Disease
- Clinical Research
-
#3
Johns Hopkins Wilmer Eye Institute
Baltimore, MD
Wilmer Eye Institute has a strong track record in translational research and clinical trials for ocular surface diseases and presbyopia, contributing to the development of new pharmacologic agents.
Key Differentiators
- Ophthalmology
- Cornea and External Disease
- Translational Research
-
#4
Duke Eye Center
Durham, NC
Duke Eye Center is notable for its clinical research in dry eye disease and presbyopia, including early-phase trials of novel topical agents targeting ocular surface and accommodative mechanisms.
Key Differentiators
- Ophthalmology
- Cornea and External Disease
- Clinical Trials
-
#5
University of California, San Francisco (UCSF) Department of Ophthalmology
San Francisco, CA
UCSF is a leader in ocular surface disease research and clinical trials, with a focus on innovative treatments for dry eye and presbyopia, including neuromodulatory approaches.
Key Differentiators
- Ophthalmology
- Cornea and External Disease
- Clinical Research
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.


